Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2025-12-29 @ 5:59 PM
Study NCT ID:
NCT05809895
Status:
WITHDRAWN
Last Update Posted:
2023-07-24
First Post:
2023-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-07-17
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07-18
Completion Date Type:
ESTIMATED
First Submit Date:
2023-03-30
First Submit QC Date:
None
Study First Post Date:
2023-04-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-21
Last Update Post Date:
2023-07-24
Last Update Post Date Type:
ACTUAL